Cerus Corp
Cerus Corp (CERS) Options Open Interest
CERS options open interest is 5,228 contracts. The 2-week average daily volume is 75 contracts across the chain.
Read more
Monitoring CERS open interest helps you see where real money is positioned on Cerus Corp's options and which strikes are attracting the most commitment from traders. Cerus Corp's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor CERS options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising CERS options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Cerus Corp to settle.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced.
It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where CERS open interest is concentrated. Our scanner maps Cerus Corp's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Cerus Corp's options open interest as the signal it is, not as an afterthought.
| 3.00 | — | 0.35 | 0.35 | 744% | +0.4678 | 293 |
| 2.00 | 0.15 | 0.95 | 0.55 | 269% | +0.9148 | 27 |
| 0.50 | 1.65 | 2.35 | 2.00 | 236% | +1.0000 | 4 |
| 1.00 | 1.15 | 1.85 | 1.50 | 145% | +1.0000 | 1 |
| 1.50 | 0.65 | 1.35 | 1.00 | 84% | +1.0000 | 0 |
| 0.50 | — | 0.05 | 0.05 | 1,000% | -0.0033 | 2 |
| 2.00 | — | 0.05 | 0.05 | 360% | -0.1405 | 1 |
| 3.00 | 0.15 | 0.85 | 0.50 | 230% | -0.8427 | 1 |
| 1.00 | — | 0.10 | 0.10 | 1,000% | -0.0446 | 0 |
| 1.50 | — | 0.35 | 0.35 | 1,000% | -0.1342 | 0 |
As of September 17, 2026
Follow the money
Track CERS open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→